The use of stereotactic body radiotherapy (SBRT) as salvage therapy after radical prostatectomy was well tolerated, with no ...

Squeezed by insurers and middlemen, independent pharmacists such as Jolley find themselves on the front lines of a tariff ...

The median age at symptom onset in the cohort was 55 years, ranging from 16 to 81 years. Data from patients’ initial ...

Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid ...

Revisions to classification criteria ‘will ensure homogeneous trial populations’ with data-driven scoring, a standardized MRI ...

The latest annual TIME100 Health list, which debuted in 2024, highlights scientists, doctors, advocates, educators, and other ...

GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by ...

After decades of hype and setbacks, scientists have made impressive progress into tricking stem cells into repairing organs.

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline: Basel Saturday, May 17, 2025, 11:00 Hrs [IST] Novartis will present data from ...

Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...

Basel, May 15, 2025 – Novartis will present data from 60 company or investigator sponsored abstracts that have the potential to change clinical practice, at the 2025 American Society of Clinical ...

At the intersection of radiation and precision, Novartis, Bayer, AstraZeneca and more hope to cash in on a ...